| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 122 | 2026 | 860 | 24.580 |
Why?
|
| Autoantibodies | 47 | 2026 | 458 | 7.600 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2026 | 1408 | 6.610 |
Why?
|
| C-Peptide | 28 | 2025 | 109 | 4.880 |
Why?
|
| Islets of Langerhans | 19 | 2024 | 163 | 4.510 |
Why?
|
| Insulin Resistance | 10 | 2025 | 696 | 3.090 |
Why?
|
| Insulin | 29 | 2025 | 1167 | 2.870 |
Why?
|
| Blood Glucose | 23 | 2025 | 1121 | 2.310 |
Why?
|
| Diabetic Ketoacidosis | 12 | 2024 | 166 | 2.310 |
Why?
|
| Adolescent | 80 | 2026 | 20524 | 2.020 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2026 | 2850 | 1.930 |
Why?
|
| Autoimmunity | 13 | 2020 | 181 | 1.920 |
Why?
|
| Genetic Predisposition to Disease | 22 | 2026 | 3358 | 1.840 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 6 | 2022 | 25 | 1.790 |
Why?
|
| Child | 83 | 2026 | 25756 | 1.770 |
Why?
|
| Hypoglycemic Agents | 12 | 2024 | 482 | 1.700 |
Why?
|
| HLA-DQ Antigens | 7 | 2024 | 22 | 1.680 |
Why?
|
| Glucose Tolerance Test | 13 | 2025 | 207 | 1.510 |
Why?
|
| Insulin-Secreting Cells | 7 | 2024 | 146 | 1.480 |
Why?
|
| Humans | 151 | 2026 | 131930 | 1.400 |
Why?
|
| Child, Preschool | 47 | 2026 | 14715 | 1.260 |
Why?
|
| Diabetes Complications | 2 | 2023 | 206 | 1.260 |
Why?
|
| Disease Progression | 23 | 2026 | 2222 | 1.160 |
Why?
|
| Male | 88 | 2026 | 64846 | 1.130 |
Why?
|
| Female | 89 | 2026 | 70607 | 1.100 |
Why?
|
| Glutamate Decarboxylase | 6 | 2017 | 42 | 1.080 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 141 | 1.080 |
Why?
|
| Young Adult | 31 | 2026 | 9929 | 1.030 |
Why?
|
| HLA-DR3 Antigen | 1 | 2024 | 1 | 0.920 |
Why?
|
| HLA-DR4 Antigen | 1 | 2024 | 6 | 0.910 |
Why?
|
| Adult | 47 | 2026 | 31506 | 0.890 |
Why?
|
| Hypoglycemia | 6 | 2018 | 183 | 0.890 |
Why?
|
| Risk Factors | 28 | 2026 | 10893 | 0.870 |
Why?
|
| Body Mass Index | 10 | 2023 | 1697 | 0.870 |
Why?
|
| Immunoglobulin A | 2 | 2024 | 218 | 0.820 |
Why?
|
| Leptin | 2 | 2023 | 219 | 0.790 |
Why?
|
| Puberty | 2 | 2021 | 104 | 0.780 |
Why?
|
| Minority Groups | 3 | 2020 | 250 | 0.760 |
Why?
|
| Prediabetic State | 4 | 2026 | 64 | 0.730 |
Why?
|
| Obesity | 10 | 2022 | 2394 | 0.720 |
Why?
|
| Infant | 24 | 2024 | 13032 | 0.720 |
Why?
|
| Biomarkers | 9 | 2024 | 3373 | 0.710 |
Why?
|
| Metformin | 1 | 2023 | 165 | 0.710 |
Why?
|
| Pediatric Obesity | 5 | 2021 | 415 | 0.710 |
Why?
|
| Genetic Linkage | 2 | 2021 | 475 | 0.690 |
Why?
|
| Hyperglycemia | 4 | 2020 | 234 | 0.680 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 114 | 0.670 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 292 | 0.650 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 348 | 0.640 |
Why?
|
| Cohort Studies | 18 | 2025 | 5143 | 0.610 |
Why?
|
| Overweight | 7 | 2020 | 383 | 0.580 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3735 | 0.570 |
Why?
|
| Flatfishes | 3 | 2006 | 3 | 0.560 |
Why?
|
| Age of Onset | 6 | 2020 | 626 | 0.560 |
Why?
|
| Fish Diseases | 3 | 2006 | 11 | 0.560 |
Why?
|
| Prospective Studies | 16 | 2024 | 6526 | 0.550 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 309 | 0.550 |
Why?
|
| Phenotype | 9 | 2024 | 4538 | 0.550 |
Why?
|
| Adiposity | 2 | 2020 | 207 | 0.540 |
Why?
|
| Age Factors | 12 | 2024 | 2920 | 0.530 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 922 | 0.530 |
Why?
|
| Precision Medicine | 4 | 2024 | 359 | 0.530 |
Why?
|
| Osteocalcin | 1 | 2017 | 46 | 0.520 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2025 | 11 | 0.510 |
Why?
|
| Protozoan Infections, Animal | 2 | 2006 | 4 | 0.500 |
Why?
|
| Prognosis | 8 | 2024 | 5004 | 0.500 |
Why?
|
| Twins, Monozygotic | 3 | 2008 | 127 | 0.490 |
Why?
|
| Hospitalization | 1 | 2024 | 1892 | 0.480 |
Why?
|
| Diseases in Twins | 2 | 2008 | 97 | 0.450 |
Why?
|
| Haplotypes | 8 | 2026 | 545 | 0.430 |
Why?
|
| Thinness | 1 | 2014 | 74 | 0.420 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 66 | 0.420 |
Why?
|
| Middle Aged | 24 | 2025 | 28893 | 0.420 |
Why?
|
| Glucose | 5 | 2023 | 878 | 0.400 |
Why?
|
| Retrospective Studies | 12 | 2026 | 17345 | 0.390 |
Why?
|
| Health Personnel | 1 | 2017 | 545 | 0.370 |
Why?
|
| Family | 4 | 2025 | 594 | 0.360 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 899 | 0.360 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 124 | 0.360 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 723 | 0.350 |
Why?
|
| Sex Factors | 6 | 2024 | 1348 | 0.350 |
Why?
|
| HLA Antigens | 4 | 2026 | 219 | 0.340 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5394 | 0.330 |
Why?
|
| Patient Preference | 1 | 2011 | 136 | 0.320 |
Why?
|
| Eukaryota | 2 | 2006 | 24 | 0.310 |
Why?
|
| Prevalence | 6 | 2024 | 2656 | 0.300 |
Why?
|
| Antibody Specificity | 3 | 2018 | 201 | 0.300 |
Why?
|
| Mass Screening | 3 | 2025 | 830 | 0.300 |
Why?
|
| Social Class | 3 | 2020 | 206 | 0.290 |
Why?
|
| Zinc Transporter 8 | 3 | 2017 | 6 | 0.290 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2026 | 23 | 0.280 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 656 | 0.260 |
Why?
|
| Twins, Dizygotic | 2 | 2004 | 46 | 0.260 |
Why?
|
| Genetic Testing | 3 | 2024 | 1098 | 0.250 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2006 | 39 | 0.240 |
Why?
|
| Abatacept | 1 | 2025 | 27 | 0.240 |
Why?
|
| Major Histocompatibility Complex | 4 | 2017 | 53 | 0.240 |
Why?
|
| Dyslipidemias | 2 | 2021 | 241 | 0.240 |
Why?
|
| Cluster Analysis | 2 | 2024 | 430 | 0.240 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2059 | 0.230 |
Why?
|
| Health Status Disparities | 2 | 2020 | 251 | 0.230 |
Why?
|
| Genotype | 6 | 2026 | 2703 | 0.220 |
Why?
|
| Social Determinants of Health | 2 | 2023 | 155 | 0.220 |
Why?
|
| Weight Gain | 3 | 2017 | 379 | 0.210 |
Why?
|
| Cytokines | 3 | 2024 | 1365 | 0.210 |
Why?
|
| Alleles | 5 | 2017 | 1684 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2024 | 748 | 0.210 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 74 | 0.210 |
Why?
|
| Siblings | 1 | 2004 | 202 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 558 | 0.200 |
Why?
|
| Fabaceae | 1 | 2023 | 21 | 0.200 |
Why?
|
| Genetic Vectors | 2 | 2017 | 926 | 0.200 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 45 | 0.200 |
Why?
|
| Immunity, Innate | 1 | 2006 | 413 | 0.200 |
Why?
|
| United States | 10 | 2025 | 11619 | 0.190 |
Why?
|
| Area Under Curve | 4 | 2025 | 319 | 0.190 |
Why?
|
| Immune System | 2 | 2020 | 97 | 0.190 |
Why?
|
| Acanthosis Nigricans | 1 | 2022 | 11 | 0.190 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 70 | 0.180 |
Why?
|
| Self-Management | 2 | 2020 | 105 | 0.180 |
Why?
|
| Celiac Disease | 2 | 2017 | 73 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2020 | 328 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 856 | 0.170 |
Why?
|
| Longitudinal Studies | 5 | 2025 | 1493 | 0.170 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.170 |
Why?
|
| Interleukin-4 | 2 | 2005 | 146 | 0.170 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 40 | 0.170 |
Why?
|
| Early Diagnosis | 1 | 2021 | 198 | 0.160 |
Why?
|
| HLA-DR2 Antigen | 1 | 1999 | 6 | 0.160 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 10 | 0.160 |
Why?
|
| HLA-DQ alpha-Chains | 4 | 2017 | 18 | 0.160 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 33 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2024 | 1579 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 26 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 482 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 130 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 273 | 0.160 |
Why?
|
| Spain | 5 | 2007 | 65 | 0.160 |
Why?
|
| Models, Immunological | 2 | 2015 | 37 | 0.150 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 1096 | 0.150 |
Why?
|
| Global Health | 1 | 2024 | 615 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.150 |
Why?
|
| Cation Transport Proteins | 2 | 2017 | 100 | 0.150 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 180 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 81 | 0.140 |
Why?
|
| Registries | 4 | 2022 | 1588 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 802 | 0.130 |
Why?
|
| Seasons | 3 | 2006 | 328 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2303 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 323 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 277 | 0.130 |
Why?
|
| Leg | 1 | 1997 | 134 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 750 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 59 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1185 | 0.130 |
Why?
|
| Communication | 2 | 2019 | 540 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 264 | 0.130 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 43 | 0.120 |
Why?
|
| Retroviridae | 1 | 2016 | 194 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2001 | 110 | 0.120 |
Why?
|
| Glucagon | 1 | 2016 | 151 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 63 | 0.120 |
Why?
|
| Exercise | 1 | 2022 | 859 | 0.120 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 66 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 236 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 64 | 0.120 |
Why?
|
| Time Factors | 5 | 2016 | 6435 | 0.120 |
Why?
|
| Roma | 1 | 1995 | 4 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 1995 | 5 | 0.120 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 811 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 78 | 0.120 |
Why?
|
| Child Development | 1 | 2017 | 271 | 0.110 |
Why?
|
| Diabetic Foot | 1 | 1997 | 167 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 348 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 248 | 0.110 |
Why?
|
| Language | 1 | 2016 | 225 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 436 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 157 | 0.110 |
Why?
|
| Adipokines | 1 | 2014 | 72 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 499 | 0.100 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 803 | 0.100 |
Why?
|
| Nuclear Family | 1 | 2013 | 51 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2017 | 661 | 0.100 |
Why?
|
| Lignans | 1 | 2012 | 6 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1521 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2020 | 8535 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 434 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 48 | 0.100 |
Why?
|
| Insulin Antibodies | 3 | 2017 | 6 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 629 | 0.090 |
Why?
|
| Flavonoids | 1 | 2012 | 85 | 0.090 |
Why?
|
| Pancreas, Artificial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Self Administration | 1 | 2011 | 52 | 0.090 |
Why?
|
| Twin Studies as Topic | 2 | 2001 | 13 | 0.090 |
Why?
|
| Stem Cells | 1 | 2016 | 732 | 0.090 |
Why?
|
| Random Allocation | 2 | 2016 | 431 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 359 | 0.090 |
Why?
|
| Oxazolidinones | 2 | 2001 | 34 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12996 | 0.080 |
Why?
|
| Quality of Life | 1 | 2021 | 2149 | 0.080 |
Why?
|
| Comorbidity | 3 | 2022 | 1604 | 0.080 |
Why?
|
| Pedigree | 3 | 2021 | 1724 | 0.080 |
Why?
|
| Diet | 2 | 2012 | 1124 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 1252 | 0.080 |
Why?
|
| Aquaculture | 2 | 2006 | 8 | 0.080 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 19 | 0.080 |
Why?
|
| Risk | 3 | 2017 | 761 | 0.080 |
Why?
|
| Pregnancy | 1 | 2022 | 7545 | 0.080 |
Why?
|
| Animals | 10 | 2017 | 34908 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3710 | 0.080 |
Why?
|
| Autoantigens | 2 | 2001 | 109 | 0.080 |
Why?
|
| Incidence | 4 | 2013 | 3362 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1450 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2016 | 893 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 133 | 0.070 |
Why?
|
| Aged | 8 | 2019 | 21394 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1757 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 993 | 0.070 |
Why?
|
| Spleen | 2 | 2006 | 271 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 1450 | 0.070 |
Why?
|
| Calpain | 1 | 2007 | 43 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1439 | 0.060 |
Why?
|
| Depression | 1 | 2015 | 1350 | 0.060 |
Why?
|
| Hypertension | 1 | 2015 | 1386 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 565 | 0.060 |
Why?
|
| Immunity, Active | 1 | 2006 | 6 | 0.060 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 6 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 28 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 91 | 0.060 |
Why?
|
| Complement Pathway, Alternative | 1 | 2006 | 14 | 0.060 |
Why?
|
| Muramidase | 1 | 2006 | 89 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 56 | 0.060 |
Why?
|
| Granulocytes | 1 | 2006 | 69 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2026 | 27 | 0.060 |
Why?
|
| Pediatrics | 1 | 2015 | 1208 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 97 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 142 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1017 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3415 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2004 | 34 | 0.060 |
Why?
|
| Probability | 1 | 2025 | 322 | 0.060 |
Why?
|
| Acetamides | 2 | 2001 | 48 | 0.050 |
Why?
|
| Family Health | 2 | 2005 | 256 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2016 | 175 | 0.050 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 316 | 0.050 |
Why?
|
| Neoplasms | 2 | 2013 | 2953 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 102 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 15 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 66 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 699 | 0.050 |
Why?
|
| Europe | 2 | 2013 | 372 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2006 | 1569 | 0.050 |
Why?
|
| Teicoplanin | 1 | 2001 | 5 | 0.050 |
Why?
|
| Coagulase | 1 | 2001 | 23 | 0.050 |
Why?
|
| Citrulline | 1 | 2023 | 114 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 209 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 449 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 79 | 0.050 |
Why?
|
| Mesonephroma | 1 | 2001 | 1 | 0.050 |
Why?
|
| Papilloma | 1 | 2001 | 22 | 0.040 |
Why?
|
| Methicillin Resistance | 1 | 2001 | 118 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 18 | 0.040 |
Why?
|
| Self Tolerance | 1 | 2001 | 6 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 100 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 341 | 0.040 |
Why?
|
| Aza Compounds | 1 | 2000 | 15 | 0.040 |
Why?
|
| United Kingdom | 1 | 2001 | 233 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 201 | 0.040 |
Why?
|
| Streptococcus | 1 | 2000 | 63 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 236 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 656 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 549 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2000 | 97 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 663 | 0.040 |
Why?
|
| Quinolines | 1 | 2000 | 122 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2001 | 2551 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1326 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1246 | 0.040 |
Why?
|
| Colectomy | 1 | 2019 | 83 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 955 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1176 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 99 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 396 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 598 | 0.040 |
Why?
|
| Artificial Limbs | 1 | 1997 | 7 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 479 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1997 | 22 | 0.030 |
Why?
|
| Pinealoma | 1 | 1997 | 23 | 0.030 |
Why?
|
| Germinoma | 1 | 1997 | 32 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2001 | 770 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 194 | 0.030 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 78 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2020 | 328 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 64 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 7113 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 163 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 473 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 400 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 189 | 0.030 |
Why?
|
| Learning | 1 | 2020 | 370 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 83 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 199 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 937 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 33 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 803 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 126 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 226 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1966 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 241 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 294 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 2724 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Rural Health | 1 | 1995 | 44 | 0.030 |
Why?
|
| Mice | 4 | 2017 | 18534 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 850 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 763 | 0.030 |
Why?
|
| Urban Health | 1 | 1995 | 78 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1478 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 329 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 996 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 579 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3977 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 226 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 240 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 2183 | 0.030 |
Why?
|
| Palliative Care | 1 | 2018 | 457 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 167 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2001 | 1596 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 794 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2141 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 712 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1285 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 38 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 623 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2013 | 73 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 813 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 1995 | 141 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1303 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 503 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1668 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1379 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1038 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 628 | 0.020 |
Why?
|
| Linezolid | 2 | 2001 | 27 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 500 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 1346 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1720 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1124 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 494 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2001 | 8 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 452 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1993 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3082 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 1410 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 2487 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 11 | 0.010 |
Why?
|
| Israel | 1 | 2005 | 48 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 67 | 0.010 |
Why?
|
| Arabs | 1 | 2005 | 30 | 0.010 |
Why?
|
| Jews | 1 | 2005 | 34 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2005 | 94 | 0.010 |
Why?
|
| Atlantic Ocean | 1 | 2004 | 2 | 0.010 |
Why?
|
| Oocysts | 1 | 2004 | 4 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2004 | 21 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 138 | 0.010 |
Why?
|
| Glutens | 1 | 2004 | 10 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2004 | 26 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 542 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 436 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1007 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 289 | 0.010 |
Why?
|
| Denmark | 1 | 2001 | 29 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 3 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 13 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 249 | 0.010 |
Why?
|
| Virginiamycin | 1 | 2000 | 3 | 0.010 |
Why?
|
| Naphthyridines | 1 | 2000 | 10 | 0.010 |
Why?
|
| Erythromycin | 1 | 2000 | 21 | 0.010 |
Why?
|
| Oxazoles | 1 | 2000 | 22 | 0.010 |
Why?
|
| Epithelium | 1 | 2001 | 354 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 197 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 796 | 0.010 |
Why?
|
| Vagina | 1 | 2001 | 206 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 364 | 0.010 |
Why?
|
| Environment | 1 | 2000 | 148 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 388 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 827 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1563 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 617 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1900 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1683 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 3852 | 0.000 |
Why?
|